SAN DIEGO, CA / ACCESSWIRE / May 9, 2024 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision medicine for immune-mediated diseases, announced the execution of provider agreements with ...

When dosing is optimized, biologics such as IFX are highly effective for managing CD and UC. Anser IFX testing uses a drug-tolerant homogeneous mobility shift assay (HMSA) to provide clinicians ...

SAN DIEGO, Oct. 20 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has been awarded U.S. Patent No. 7,592,437 by the U.S. Patent and Trademark ...

Anser testing was first launched in 2012 and has been cited in over 100 peer-reviewed publications or abstracts. Nearly 480,000 Anser tests have been performed for more than 220,000 unique patients.